Hoang-Chuong Nguyen Vu, MD
Family Medicine · San Bernardino, CANPI 1922135086
Payments from drug & device makers
Across 36 payments — averaging $45.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bayer$413
- Lilly USA, LLC$250
- Johnson & Johnson$172
- Novo Nordisk$134
- Boehringer Ingelheim$132
- Sumitomo Pharma America, Inc.$125
- plus $416 from 8 others
Across 4 payments — averaging $34.70 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Teva Pharmaceuticals USA, Inc.$139
What the payments were for
- Food & beverage$1,640100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bayer | 9 | $413 |
| Lilly USA, LLC | 2 | $250 |
| Johnson & Johnson | 9 | $172 |
| Novo Nordisk | 2 | $134 |
| Boehringer Ingelheim | 2 | $132 |
| Sumitomo Pharma America, Inc. | 1 | $125 |
| Gilead | 1 | $123 |
| Amgen | 1 | $117 |
| AbbVie | 3 | $67 |
| Pfizer | 2 | $41 |
| Merck | 1 | $23 |
| Sunovion Pharmaceuticals Inc. | 1 | $19 |
| Otsuka America Pharmaceutical, Inc. | 1 | $14 |
| AstraZeneca | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,640 in reported general payments places this provider in the 80th percentile of 10,533 family medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 275 | $151,300 |
| JanuviaSitagliptin Phosphate | 221 | $139,285 |
| JardianceEmpagliflozin | 175 | $109,646 |
| XareltoRivaroxaban | 160 | $89,180 |
| FarxigaDapagliflozin Propanediol | 80 | $47,635 |
| OzempicSemaglutide | 46 | $44,643 |
| Omeprazole-Sodium BicarbonateOmeprazole/Sodium Bicarbonate | 26 | $37,770 |
| MyrbetriqMirabegron | 62 | $30,678 |
| TradjentaLinagliptin | 65 | $30,615 |
| KerendiaFinerenone | 36 | $28,293 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 33 | $24,678 |
| LinzessLinaclotide | 46 | $24,508 |
| TrulicityDulaglutide | 20 | $19,323 |
| EntrestoSacubitril/Valsartan | 31 | $18,293 |
| RexultiBrexpiprazole | 17 | $16,468 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Premarin | $41 | $155,915289 claims |
| Boehringer IngelheimJardiance, Tradjenta, Combivent Respimat, Synjardy Xr | $132 | $155,206272 claims |
| MerckJanuvia, Janumet, Steglatro | $23 | $153,643260 claims |
| Johnson & JohnsonXarelto | $172 | $89,180160 claims |
| Novo NordiskOzempic, Rybelsus | $134 | $58,26260 claims |
| AstraZenecaFarxiga, Brilinta | $12 | $55,64097 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $250 | $34,83734 claims |
| AbbVieLinzess, Restasis | $67 | $33,06859 claims |
| BayerKerendia | $413 | $28,29336 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $14 | $16,46817 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 10,533 family medicine providers in California.
Other family medicine in San Bernardino
- Amina HaggagNorthridge$112.8M
- Steven ReynoldsLong Beach$53M
- Rizwana MohseniLake Forest$26.7M
- Daniel JohnsonSan Diego$15.7M
- Stacey LayleSan Diego$14.8M
- Apinya VutikullirdCypress$14.3M
- Hanid AudishSpring Valley$13.6M
- Augusto FocilOxnard$12.6M
- Jack VuLong Beach$10.1M
- Suzanne FussellOxnard$8.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.